Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Tislelizumab for the Treatment of Patients with Mismatch Repair Deficient Metastatic Colorectal Cancer or Stage II or III Rectal Cancer

Trial Status: approved

This phase II trial tests how well tislelizumab works in treating patients with mismatch repair deficient colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or stage II or III rectal cancer. Tislelizumab is a type of drug called a PD-1 inhibitor. It is designed to block a protein called programmed cell death protein 1, which acts as a “brake” on the immune system. Blocking this protein is like releasing the brakes, so the immune system can target tumor cells and destroy them.